=Prothena (PRTA) reported earnings on Tue 8 Aug 2017 (a/h)

Prothena beats by $0.35, beats on revs

• Reports Q2 (Jun) loss of $0.46 per share, $0.35 better than the Capital IQ Consensus of ($0.81); revenues rose 7951.1% year/year to $26.81 mln vs the $16.08 mln Capital IQ Consensus.
• Upcoming Research and Development Milestones
• NEOD001 is a monoclonal antibody for the potential treatment of AL amyloidosis:
  • Topline results in the Phase 2b PRONTO study (129 patients) expected in the second quarter of 2018;
• PRX003 is a monoclonal antibody for the potential treatment of inflammatory diseases, including psoriasis and psoriatic arthritis:
  • Topline results from the Phase 1b multiple ascending dose, safety and proof-of-biology study in 32 patients (8 patients per dose-level cohort, randomized 3:1) with psoriasis expected in October 2017;
• PRX004 is a monoclonal antibody for the potential treatment of ATTR amyloidosis:
  • Clinical development expected to begin by mid-2018.